The impact of fragility fracture and approaches to osteoporosis risk assessment worldwide

Bone

Volumn 104, Issue , 2017, Pages 29-38

  Curtis, Elizabeth M ^a   Moon, Rebecca J ^a,b   Harvey, Nicholas C ^a,b   Cooper, Cyrus ^a,b,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Assessment; Epidemiology; Geography; High fracture risk; Osteoporosis

Indexed keywords

ARTICLE; BONE DENSITY; CASE FINDING; DISEASE ASSOCIATION; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNIC DIFFERENCE; FRACTURE TREATMENT; FRAGILITY FRACTURE; GEOGRAPHIC DISTRIBUTION; GLOBAL DISEASE BURDEN; GLOBAL HEALTH; HEALTH CARE COST; HEALTH CARE POLICY; HIGH RISK PATIENT; HUMAN; INCIDENCE; MUSCULOSKELETAL DISEASE ASSESSMENT; ORTHOPEDIC SOFTWARE; OSTEOPOROSIS; PRIMARY PREVENTION; PUBLIC HEALTH PROBLEM; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; TREATMENT OUTCOME; ALGORITHM; CHRONIC DISEASE; DIAGNOSTIC IMAGING; PATHOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY;

ABSORPTIOMETRY, PHOTON; ALGORITHMS; BONE DENSITY; CHRONIC DISEASE; HUMANS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK ASSESSMENT;

EID: 85011031806     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2017.01.024     Document Type: Article

References (95)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am. J. Med., 94(6), 1993, 646–650.
2. World Health Organization Study, G, Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. 1994.
3. Kanis, J.A., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 18:8 (2007), 1033–1046.
4. Murray, C.J., et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet 386:10009 (2015), 2145–2191.
5. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 386(9995), 2015, 743–800.
6. Bone Health and Osteoporosis: A Report of the Surgeon General. 2004 (Rockville MD).
7. Hernlund, E., et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch. Osteoporos., 8(1–2), 2013, 136.
8. van Staa, T.P., et al. Epidemiology of fractures in England and Wales. Bone 29:6 (2001), 517–522.
9. Kanis, J.A., et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos. Int. 23:9 (2012), 2239–2256.
10. Srinivasan, B., et al. Relationship of femoral neck areal bone mineral density to volumetric bone mineral density, bone size, and femoral strength in men and women. Osteoporos. Int. 23:1 (2012), 155–162.
11. Kanis, J.A., et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22:11 (2011), 2789–2798.
12. Johnell, O., et al. Predictive value of BMD for hip and other fractures. J. Bone Miner. Res. 20:7 (2005), 1185–1194.
13. The Eastern European & Central Asian Regional Audit Epidemiology, costs & burden of osteoporosis in 2010. International Osteoporosis Foundation. Nyon., 2011.
14. Cauley, J.A., et al. Official positions for FRAX(R) clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). J. Clin. Densitom. 14:3 (2011), 240–262.
15. Elffors, I., et al. The variable incidence of hip fracture in southern Europe: the MEDOS study. Osteoporos. Int. 4:5 (1994), 253–263.
16. Johnell, O., et al. Latitude, socioeconomic prosperity, mobile phones and hip fracture risk. Osteoporos. Int. 18:3 (2007), 333–337.
17. Bacon, W.E., Hadden, W.C., Occurrence of hip fractures and socioeconomic position. J. Aging Health 12:2 (2000), 193–203.
18. Curtis, E.M., et al. Epidemiology of fractures in the United Kingdom 1988–2012: variation with age, sex, geography, ethnicity and socioeconomic status. Bone 87 (2016), 19–26.
19. Johnell, O., et al. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J. Bone Miner. Res. 10:11 (1995), 1802–1815.
20. Kanis, J.A., Passmore, R., Calcium supplementation of the diet—I. BMJ 298:6667 (1989), 137–140.
21. Kanis, J.A., Passmore, R., Calcium supplementation of the diet—II. BMJ 298:6668 (1989), 205–208.
22. Wright, N.C., et al. Recent trends in hip fracture rates by race/ethnicity among older US adults. J. Bone Miner. Res. 27:11 (2012), 2325–2332.
23. Solomon, L., Osteoporosis and fracture of the femoral neck in the South African Bantu. J. Bone Joint Surg. (Br.) 50:1 (1968), 2–13.
24. Silverman, S.L., Madison, R.E., Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California Hospital Discharge Data. Am. J. Public Health 78:11 (1988), 1482–1483.
25. Yang, P.L., et al. Associations between ethnicity, body composition, and bone mineral density in a Southeast Asian population. J. Clin. Endocrinol. Metab. 98:11 (2013), 4516–4523.
26. Goh, J.C., Low, S.L., Das De, S., Bone mineral density and hip axis length in Singapore's multiracial population. J. Clin. Densitom. 7:4 (2004), 406–412.
27. Putman, M.S., et al. Differences in skeletal microarchitecture and strength in African-American and white women. J. Bone Miner. Res. 28:10 (2013), 2177–2185.
28. Araujo, A.B., et al. Race/ethnic differences in bone mineral density in men. Osteoporos. Int. 18:7 (2007), 943–953.
29. Looker, A.C., et al. Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J. Bone Miner. Res. 25:1 (2010), 64–71.
30. Nations, U., World Population Prospects: The 2015 Revision. 2015, New York, United Nations.
31. Cooper, C., Campion, G., Melton, L.J., Hip fractures in the elderly: a world-wide projection. Osteoporos. Int. 2:6 (1992), 285–289.
32. Gullberg, B., Johnell, O., Kanis, J.A., World-wide projections for hip fracture. Osteoporos. Int. 7:5 (1997), 407–413.
33. Cooper, C., et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos. Int. 22:5 (2011), 1277–1288.
34. van der Velde, R.Y., et al. Secular trends in fracture incidence in the UK between 1990 and 2012. Osteoporos. Int. 27:11 (2016), 3197–3206.
35. Lau, E.M., et al. Hip fracture in Hong Kong over the last decade—a comparison with the UK. J. Public Health Med. 21:3 (1999), 249–250.
36. Xu, L., et al. Very low rates of hip fracture in Beijing, People's Republic of China the Beijing Osteoporosis Project. Am. J. Epidemiol. 144:9 (1996), 901–907.
37. Koh, L.K., et al. Hip fracture incidence rates in Singapore 1991–1998. Osteoporos. Int. 12:4 (2001), 311–318.
38. Tsukutani, Y., et al. Epidemiology of fragility fractures in Sakaiminato, Japan: incidence, secular trends, and prognosis. Osteoporos. Int. 26:9 (2015), 2249–2255.
39. Cooper, C., et al. Secular trends in the incidence of postmenopausal vertebral fractures. Calcif. Tissue Int. 51:2 (1992), 100–104.
40. Islam, S., et al. Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000–2005. Menopause 16:1 (2009), 77–83.
41. Bengner, U., Johnell, O., Redlund-Johnell, I., Changes in incidence and prevalence of vertebral fractures during 30 years. Calcif. Tissue Int. 42:5 (1988), 293–296.
42. Kim, T.Y., et al. Trends of incidence, mortality, and future projection of spinal fractures in Korea using nationwide claims data. J. Korean Med. Sci. 31:5 (2016), 801–805.
43. Siggeirsdottir, K., et al. Epidemiology of fractures in Iceland and secular trends in major osteoporotic fractures 1989–2008. Osteoporos. Int. 25:1 (2014), 211–219.
44. Oden, A., et al. Burden of high fracture probability worldwide: secular increases 2010–2040. Osteoporos. Int. 26:9 (2015), 2243–2248.
45. Grover, M.L., et al. Fracture risk perception study: patient self-perceptions of bone health often disagree with calculated fracture risk. Womens Health Issues 24:1 (2014), e69–e75.
46. Gregson, C.L., et al. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos. Int. 25:1 (2014), 85–95.
47. Eisman, J.A., et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J. Bone Miner. Res. 27:10 (2012), 2039–2046.
48. Mitchell, P.J., Best practices in secondary fracture prevention: fracture liaison services. Curr. Osteoporos. Rep. 11:1 (2013), 52–60.
49. Drew, S., et al. Secondary prevention of fractures after hip fracture: a qualitative study of effective service delivery. Osteoporos. Int. 27:5 (2016), 1719–1727.
50. Akesson, K., et al. Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos. Int. 24:8 (2013), 2135–2152.
51. Greenspan, S.L., et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J. Am. Geriatr. Soc. 60:3 (2012), 455–461.
52. Mitchell, P., et al. Implementation of models of care for secondary osteoporotic fracture prevention and orthogeriatric models of care for osteoporotic hip fracture. Best Pract. Res. Clin. Rheumatol. 30:3 (2016), 536–558.
53. Cooper, C., et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985–1989. J. Bone Miner. Res. 7:2 (1992), 221–227.
54. Clark, E.M., et al. Randomized controlled trial of a primary care-based screening program to identify older women with prevalent osteoporotic vertebral fractures: cohort for Skeletal Health in Bristol and Avon (COSHIBA). J. Bone Miner. Res. 27:3 (2012), 664–671.
55. Clark, E.M., Gooberman-Hill, R., Peters, T.J., Using self-reports of pain and other variables to distinguish between older women with back pain due to vertebral fractures and those with back pain due to degenerative changes. Osteoporos. Int. 27:4 (2016), 1459–1467.
56. Cosman, F., et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos. Int. 25:10 (2014), 2359–2381.
57. Kanis, J.A., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 24:1 (2013), 23–57.
58. Lekamwasam, S., et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos. Int. 23:9 (2012), 2257–2276.
59. Lekamwasam, S., et al. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch. Osteoporos. 7:1–2 (2012), 25–30.
60. Shepstone, L., et al. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos. Int. 23:10 (2012), 2507–2515.
61. McCloskey, E., Lenaghan, E., Clarke, S., Fordham, R., Gittoes, N., Harvey, I., Holland, R., Howe, A., Marshall, T., Peters, T., Kanis, J., O'Neill, T., Torgerson, D., Cooper, C., Shepstone, L., Screening based on FRAX fracture risk assessment reduces the incidence of hip fractures in older community-dwelling women – results from the SCOOP study: Abstracts of Osteoporosis Conference 2016. Osteoporos. Int. 27:2 (2016), 609–685.
62. Marshall, D., Johnell, O., Wedel, H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:7041 (1996), 1254–1259.
63. Wainwright, S.A., et al. Hip fracture in women without osteoporosis. J. Clin. Endocrinol. Metab. 90:5 (2005), 2787–2793.
64. Kanis, J.A., et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos. Int. 18:8 (2007), 1033–1046.
65. Kanis, J.A., et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19:4 (2008), 385–397.
66. Hippisley-Cox, J., Coupland, C., Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ, 344, 2012, e3427.
67. Moon, R.J., Harvey, N.C., Identification of patient profile for treatment. Best Pract. Res. Clin. Endocrinol. Metab. 28:6 (2014), 767–782.
68. Kanis, J.A., et al. Worldwide uptake of FRAX. Arch. Osteoporos., 9(1), 2014, 166.
69. Leslie, W.D., et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos. Int. 23:1 (2012), 75–85.
70. Olmez Sarikaya, N., et al. Agreement between FRAX scores calculated with and without bone mineral density in women with osteopenia in Turkey. Clin. Rheumatol., 2014.
71. McCloskey, E.V., et al. FRAX updates 2016. Curr. Opin. Rheumatol. 28:4 (2016), 433–441.
72. van Staa, T.P., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:12 (2000), 1383–1389.
73. van Staa, T.P., et al. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. JID 15:6 (2000), 993–1000 8610640.
74. Kanis, J.A., et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos. Int. 22:3 (2011), 809–816.
75. Leslie, W.D., et al. Does osteoporosis therapy invalidate FRAX for fracture prediction?. J. Bone Miner. Res. 27:6 (2012), 1243–1251.
76. Kanis, J.A., et al. Smoking and fracture risk: a meta-analysis. Osteoporos. Int. 16:2 (2005), 155–162.
77. Kanis, J.A., et al. Interpretation and use of FRAX in clinical practice. Osteoporos. Int. 22:9 (2011), 2395–2411.
78. Harvey, N.C., et al. FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos. Int. 27:1 (2016), 267–274.
79. Nguyen, N.D., et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos. Int. 19:10 (2008), 1431–1444.
80. Hippisley-Cox, J., Coupland, C., Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ, 339, 2009, b4229.
81. Cooper, C., Harvey, N.C., Osteoporosis risk assessment. BMJ, 344, 2012, e4191.
82. Hippisley-Cox, J., Coupland, C., Brindle, P., The performance of seven QPrediction risk scores in an independent external sample of patients from general practice: a validation study. BMJ Open, 4(8), 2014, e005809.
83. Kanis, J.A., et al. SIGN guidelines for Scotland: BMD versus FRAX versus QFracture. Calcif. Tissue Int. 98:5 (2016), 417–425.
84. Leslie, W.D., Schousboe, J.T., A review of osteoporosis diagnosis and treatment options in new and recently updated guidelines on case finding around the world. Curr. Osteoporos. Rep. 9:3 (2011), 129–140.
85. Kanis, J.A., et al. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch. Osteoporos., 11(1), 2016, 25.
86. National Osteoporosis Foundation, Clinician's Guide to the Prevention and Treatment of Osteoporosis. 2013, National Osteoporosis Foundation, Washington DC.
87. Compston, J., et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas, 2013.
88. Kanis, J.A., et al. SCOPE: a scorecard for osteoporosis in Europe. Arch. Osteoporos., 8, 2013, 144.
89. Overman, R.A., et al. DXA utilization between 2006 and 2012 in commercially insured younger postmenopausal women. J. Clin. Densitom. 18:2 (2015), 145–149.
90. Giangregorio, L., et al. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin. Arthritis Rheum. 35:5 (2006), 293–305.
91. Kanis, J.A., et al. The osteoporosis treatment gap. J. Bone Miner. Res. 29:9 (2014), 1926–1928.
92. Solomon, D.H., et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J. Bone Miner. Res. 29:9 (2014), 1929–1937.
93. van der Velde, R.Y., et al. Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone 94 (2016), 50–55.
94. Adler, R.A., et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 31:1 (2016), 16–35.
95. Abrahamsen, B., et al. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ, 353, 2016, i3365.